U.S. Endocrine Testing Market Size & Outlook, 2023-2030
U.S. endocrine testing market, 2018-2030 (US$M)
Related Markets
U.S. endocrine testing market highlights
- The U.S. endocrine testing market generated a revenue of USD 4,327.2 million in 2023 and is expected to reach USD 7,216.7 million by 2030.
- The U.S. market is expected to grow at a CAGR of 7.6% from 2024 to 2030.
- In terms of segment, thyroid stimulating hormone (tsh) test was the largest revenue generating test type in 2023.
- Insulin Test is the most lucrative test type segment registering the fastest growth during the forecast period.
Endocrine testing market data book summary
| Market revenue in 2023 | USD 4,327.2 million |
| Market revenue in 2030 | USD 7,216.7 million |
| Growth rate | 7.6% (CAGR from 2023 to 2030) |
| Largest segment | Thyroid stimulating hormone (tsh) test |
| Fastest growing segment | Insulin Test |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (hCG) Hormone Test, Luteinizing Hormone (LH) Test, Dehydroepiandrosterone Sulfate (DHEAS) Test, Progesterone Test, Testosterone Test, Thyroid Stimulating Hormone (TSH) Test, Prolactin Test, Cortisol Test, Insulin Test |
| Key market players worldwide | Abbott Laboratories, Danaher Corp, Agilent Technologies Inc, BioMerieux SA, Bio-Rad Laboratories Inc, Diasorin SpA, Roche Holding AG ADR, Labcorp Holdings Inc, Quest Diagnostics Inc, QuidelOrtho Corp |
Other key industry trends
- In terms of revenue, U.S. accounted for 35.5% of the global endocrine testing market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. endocrine testing market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 7,216.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Endocrine Testing Market Scope
Endocrine Testing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. endocrine testing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to endocrine testing market will help companies and investors design strategic landscapes.
Thyroid stimulating hormone (tsh) test was the largest segment with a revenue share of 28% in 2023. Horizon Databook has segmented the U.S. endocrine testing market based on estradiol (e2) test, follicle stimulating hormone (fsh) test, human chorionic gonadotropin (hcg) hormone test, luteinizing hormone (lh) test, dehydroepiandrosterone sulfate (dheas) test, progesterone test, testosterone test, thyroid stimulating hormone (tsh) test, prolactin test, cortisol test, insulin test covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to U.S. endocrine testing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. endocrine testing market databook
-
Our clientele includes a mix of endocrine testing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. endocrine testing market , including forecasts for subscribers. This country databook contains high-level insights into U.S. endocrine testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. endocrine testing market size, by test type, 2018-2030 (US$M)
U.S. Endocrine Testing Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
